DE TURSI, Michele
 Distribuzione geografica
Continente #
NA - Nord America 3.278
EU - Europa 2.556
AS - Asia 791
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 6
AF - Africa 3
OC - Oceania 2
Totale 6.647
Nazione #
US - Stati Uniti d'America 3.270
IE - Irlanda 700
IT - Italia 473
SE - Svezia 426
CN - Cina 423
UA - Ucraina 278
FR - Francia 210
TR - Turchia 186
GB - Regno Unito 162
DE - Germania 118
IN - India 114
BE - Belgio 93
VN - Vietnam 48
FI - Finlandia 42
AT - Austria 12
EU - Europa 11
PL - Polonia 10
CA - Canada 6
CZ - Repubblica Ceca 6
RO - Romania 6
JP - Giappone 5
PT - Portogallo 4
ES - Italia 3
GR - Grecia 3
SG - Singapore 3
CL - Cile 2
CO - Colombia 2
HK - Hong Kong 2
NL - Olanda 2
PK - Pakistan 2
TW - Taiwan 2
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
DZ - Algeria 1
ID - Indonesia 1
IL - Israele 1
IR - Iran 1
KR - Corea 1
LV - Lettonia 1
MA - Marocco 1
MM - Myanmar 1
MT - Malta 1
MX - Messico 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PY - Paraguay 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 6.647
Città #
Chandler 897
Dublin 675
Jacksonville 468
Princeton 270
Ashburn 191
Nanjing 131
Izmir 120
Southend 116
Chieti 113
Dearborn 107
Wilmington 107
Altamura 101
Beijing 93
Brussels 92
Ann Arbor 89
Cambridge 55
New York 48
Dong Ket 47
Boardman 44
Washington 39
Menlo Park 36
Nanchang 32
Shenyang 24
Norwalk 22
Hebei 20
Kunming 20
Falls Church 19
Pescara 19
Woodbridge 19
Tianjin 16
Houston 15
Rome 15
Seattle 15
Jiaxing 13
Hangzhou 12
Vienna 12
Edinburgh 11
Pune 9
Redwood City 9
Grevenbroich 8
Kraków 8
Changchun 7
Hefei 7
Changsha 6
Mcallen 6
Giaveno 5
Guangzhou 5
Lanciano 5
Pisa 5
Simi Valley 5
Tappahannock 5
Tokyo 5
L’Aquila 4
Rouen 4
Shanghai 4
Altino 3
Ameno 3
Aprilia 3
Auburn Hills 3
Bangalore 3
Ferrero 3
Garden City 3
Helsinki 3
Jinan 3
Lanzhou 3
London 3
Madrid 3
Milan 3
Montreal 3
Paris 3
Prague 3
Redmond 3
Shaoxing 3
Sulmona 3
Tucson 3
Amsterdam 2
Andover 2
Antrodoco 2
Bari 2
Bogotá 2
Bordeaux 2
Boston 2
Brno 2
Chengdu 2
Chicago 2
Collecorvino 2
Fairfield 2
Haikou 2
Hong Kong 2
Isernia 2
Islamabad 2
Jinhua 2
Leawood 2
Leicester 2
Lisbon 2
Loreto Aprutino 2
Montorio al Vomano 2
New Delhi 2
Ningbo 2
Pistoia 2
Totale 4.340
Nome #
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 95
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 94
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 93
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 93
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 92
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 90
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 83
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 82
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 82
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 81
Principali effetti collaterali delle terapie mediche 81
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 79
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 78
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 77
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 75
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 75
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 73
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 73
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 72
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 72
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 72
Speed rate (SR) as a new dynamic index of melanoma behavior 72
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 71
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 71
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 71
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 70
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 70
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 70
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 70
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 69
Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group 69
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 68
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 68
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 67
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 66
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 66
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 66
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 66
Rivaroxaban for cancer-associated cardiac thrombosis 65
null 65
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 64
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 64
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 64
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 63
New Targets for Therapy in Pancreatic Cancer 62
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 62
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 62
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 61
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 61
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 61
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 60
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 60
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 60
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 60
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 59
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 58
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 58
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 58
null 57
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 57
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 56
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 56
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 56
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 56
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 55
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 54
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 54
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 54
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 53
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 53
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 53
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 52
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 52
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 52
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 51
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 51
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. 50
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 50
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 50
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 50
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 49
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. 48
Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP) 47
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 47
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 47
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 47
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 46
Poor risk metastatic renal cell carcinoma (mRCC) patients are not a homogeneous group: a new stratificating model in the era of targeted therapy. 45
Nivolumab and diabetes mellitus: safe administration in a patient with pancreatic metastases from melanoma 45
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 45
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 45
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review 44
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. 44
null 44
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 44
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 44
High blood concentration of circulating cancer stem cell-derived extracellular vesicles is associated with poor survival in advanced colorectal cancer patients 42
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 41
Totale 6.275
Categoria #
all - tutte 24.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.554

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019190 0 0 0 0 0 0 0 5 17 12 6 150
2019/20201.235 322 51 18 25 98 93 148 75 72 143 174 16
2020/2021835 125 30 157 21 55 172 33 24 59 53 30 76
2021/2022828 19 28 17 198 76 26 22 45 51 20 74 252
2022/20232.434 211 328 192 262 171 421 138 242 277 24 114 54
2023/2024938 67 43 82 36 82 407 181 40 0 0 0 0
Totale 7.389